Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15141MR)

This product GTTS-WQ15141MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases, Pemphigus vulgaris (PV) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15141MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5425MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ6275MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ11543MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ6272MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ546MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ8429MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ7732MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ15856MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW